Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance tOcisplatin, taxol, and gefitinib

Aim： To Characterize a new human lung cancer cell line Am1010, derived from drug-surviving cells （DSCs）. Methods： The Am1010 cell line was established after 4 cycles of chemotherapy from an arm muscle metastasic tumor of a patient diagnosed with lung adenocarcinoma. The cell line has been remained in continuous culture for more than one year during this study. Results： The Am1010 cell line demonstrated in vitro multi-drug-resistance to cisplatin, taxol, and gefitinib. The Am1010 cell doubling time without drug treatment was 42.395 h. The IC50 value of cisplatin was 4.299 pmol/L and 〉10 IJmol/L for the Am1010 and P0318 （a cell line derived from non-DSCs） cells, respectively. The IC50 value of taxol was 0.067 μmol/L and 〉1 IJmol/L for the Am1010 and P0318 cells, respectively. The IC50 ovalue of gefitinib was 15.233 μmol/L and 〉70 μmol/L for Am1010 and P0318 cells, respectively. 11 genes involved in the focal adhesion and cell adhesion pathways were found to be differentially expressed. The cells of Am1010 have a significantly larger chromosome number than most lung cancer cell lines. Conclusion： This novel DSCs derived lung cancer cell line will be a valuable in vitro tool for the investigation of lung cancer drug resistance and metastasis.